Clinical Trial Update: Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy and safety of dupilumab in participants aged 12 to under 18 with moderate-to-severe atopic dermatitis; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic | Phase 3 | Status: COMPLETED | Results posted: 2019-07-23